Key result
The Alere i Influenza A&B assay demonstrated sensitivities of 65.96% and 53.33% for influenza A and B, respectively, and specificities of 98.51% and 95.96% compared to molecular techniques.
Why the study?
Does the Alere i Influenza A&B assay accurately detect influenza A and B viruses compared to molecular techniques in inpatients with influenza-like illness?
Observational (n=119)
Does the Alere i Influenza A&B assay accurately detect influenza A and B viruses compared to molecular techniques in inpatients with influenza-like illness?
The Alere i Influenza A&B assay is more sensitive than the BinaxNOW card but has moderate sensitivity compared to gold-standard molecular techniques, while maintaining excellent specificity.
No takes yet. Share an insight, caveat, or question.
Moderate sensitivity cautions against sole use to rule out influenza in inpatients; leaves open need for prospective validation versus molecular standards.
Chiarella et al. (2016) conducted an observational in influenza-like illness (n=119). Alere i Influenza A&B assay vs. Molecular techniques and Alere BinaxNOW Influenza A & B Card was evaluated on Detection of influenza A and B viruses. The Alere i Influenza A&B assay demonstrated sensitivities of 65.96% and 53.33% for influenza A and B, respectively, and specificities of 98.51% and 95.96% compared to molecular techniques.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: